Marksans Pharma submits FY26 Annual Report, reports record revenue of Rs 3,033 cr
MARKSANS · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
On the reaction day the stock moved 2.2 pts more than Nifty Microcap 250 and 2.7 pts more than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.
Minute windows have no benchmark: there is no intraday index history to compare against.
Marksans Pharma filed its FY2025-26 Annual Report with BSE and NSE. Revenue crossed Rs 3,000 cr for the first time at Rs 3,033 cr, with operating revenue up 12.5% YoY at Rs 2,951 cr. PAT hit a record Rs 420 cr, while EBITDA stood at Rs 601 cr at a 20.4% margin. North America revenue surged 24% to Rs 1,533 cr. The company holds a debt-free balance sheet with about Rs 990 cr in cash. Board has recommended a final dividend of Rs 0.90 per share. The 34th AGM is scheduled for August 27, 2026 via video conference.
Record profit, debt-free balance sheet, and strong revenue growth are positive for shareholders. Final dividend of Rs 0.90 per share declared.